PIK3CD and T-cell non-Hodgkin lymphoma: Duvelisib is an oral inhibitor of phosphatidylinositol-3 protein kinase (PI3K) isoforms delta and gamma and is currently being tested in clinical trials for the treatment of T-Cell lymphoma.